

19) Europäischer Patentamt  
European Patent Office  
Office européen des brevets



11) Publication number:

0 273 716 B1

12)

## EUROPEAN PATENT SPECIFICATION

15) Date of publication of patent specification: 11.08.93 51) Int. Cl. 5: C07K 7/08, C07K 7/10,  
//A61K37/02, A61K39/21  
21) Application number: 87311391.4  
22) Date of filing: 23.12.87

### 54) Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins.

30) Priority: 30.12.86 US 947935  
12.02.87 US 14430  
43) Date of publication of application:  
06.07.88 Bulletin 88/27  
45) Publication of the grant of the patent:  
11.08.93 Bulletin 93/32  
84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE  
56) References cited:

PROCEEDINGS OF THE NATL. ACADEMY OF  
SCIENCE USA, vol. 82, no. 20, October 1985;  
pages 7048-7052, C. DeLisi et al.: "T-cell an-  
tigenic sites tend to be amphipathic struc-  
tures"

73) Proprietor: THE UNITED STATES OF AMERICA  
as represented by the Secretary, United  
States Department of Commerce  
National Technical Information Service, Of-  
fice of Government Inventions and Patents,  
5285 Port Royal Road  
Springfield, Virginia 22161(US)  
72) Inventor: Berzofsky, Jay A.  
9321 Corsica Drive  
Bethesda, MD 20814(US)  
Inventor: Cease, Kemp B.  
2006 Baltimore Road, Apt. D43  
Rockville, MD 20851(US)  
Inventor: DeLisi, Charles  
7805 Radnor Road  
Bethesda, MD 20814(US)  
Inventor: Margalit, Hanah  
252 Congressional Lane, Apt. 102  
Rockville, MD 20852(US)  
Inventor: Cornette, James L.  
2814 Torrey Pines Circle  
Ames, IA 50010(US)  
Inventor: Ouyang, Cecilia Spencer  
1915 Winnexburg Court, Apt. 101  
Silver Spring, MD 20906(US)

EP 0 273 716 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

CHEMICAL ABSTRACTS, vol. 104, no. 5, 03  
February 1986, pag 290, abstract 31295v,  
Columbus, Ohio, US; D. PAULETTI et al.:  
"Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein", & ANAL. BIOCHEM. 1985,  
151(2), 540-6

CHEMICAL ABSTRACTS, vol. 107, no. 9, 31  
August 1987, Columbus, OH (US); K.B. CEASE  
et al., p. 530, no. 75749n&NUM;

⑦4 Representative: Jump, Tim thy John Simon et  
al  
F.J. Cleveland and Company 40-43 Chancery  
Lane  
London WC2A 1JQ (GB)

**Description**

The purpose of the present invention is to develop a vaccine to prevent acquired immunodeficiency syndrome (AIDS) based partly or solely on synthetic peptides which produce T cell immunity. T cell immunity is an important arm of defense against viral infections, but has hardly been studied for AIDS. Helper T cells are needed for an antibody response as well as for a cytotoxic T cell response and for inducing macrophage and LAK cell killing. While it is not yet clear whether cellular immunity or humoral immunity is the critical element in protection against a virus, the peptides of the present invention are particularly suited for use in a vaccine capable of safely eliciting either type of immunity: (1) the peptides are synthetically produced, and therefore do not include live virus, or a part of a live virus, or other sites which might produce deleterious effects (e.g., the site binding to T4 or the site producing cell fusion); (2) the peptides may be used alone to induce cellular immunity; (3) the peptides may be used in conjunction with other molecules in order to induce antibody production or a humoral response; and (4) the peptides may be targeted for a particular type of T-cell response without the side effects of other unwanted responses.

Much effort has been devoted to the analysis of antibodies to AIDS virus antigens, but no previous studies have defined antigenic sites of this virus which elicit T cell immunity, even though such immunity is important in protection against many other viruses. Analysis of immunodominant helper T cell sites has suggested that such sites tend to form amphipathic helices. Using an algorithm based on this model, two candidate T cell sites, env T1 and env T2, were identified in the human T cell lymphotropic virus type IIb (HTLV-IIb) envelope protein that were conserved in other Human Immunodeficiency Virus (HIV) isolates. Corresponding peptides were synthesized and studied in genetically defined inbred and F<sub>1</sub> mice for induction of lymph node proliferation. After immunization with a 425 residue recombinant envelope protein fragment, significant responses to native gp120 as well as to each peptide were observed in both F<sub>1</sub> combinations studied. Conversely, immunization with env T1 peptide induced T cell immunity to the native gp120 envelope protein. The genetics of the response to env T1 peptide were further examined and revealed a significant response in three of four independent Major Histocompatibility haplotypes tested, an indication of high frequency responsiveness in the population.

Identification of helper T cell sites should facilitate development of a highly immunogenic, carrier-free vaccine that induces both T cell and B cell immunity. The ability to elicit T cell immunity to the native AIDS viral protein by immunization with a 16-residue peptide suggests that such sites represent potentially important components of an effective AIDS vaccine.

Since the discovery of the human immunodeficiency viruses, the causative agents of the acquired immunodeficiency syndrome (AIDS), substantial progress has been made toward characterizing the viral genes and their products in infected cells. Though responsible for profound immunodeficiency, viral infection in man consistently induces a detectable immune response as evidenced by serum antibodies to the major viral proteins. Studies of serum reactivity to specific viral proteins have revealed no consistent prognostic associations to date. Much of the host antibody response is focused on the envelope proteins gp120 and gp41. The ability of native gp120 or a large recombinant fragment to induce neutralizing antibodies has been demonstrated. Two apparently immunodominant antibody binding sites in the gp41 envelope protein have been defined at the level of small synthetic peptides. Though such antibody sites are clearly of diagnostic importance and potentially of importance for vaccine design, the typical progression of AIDS in patients despite the presence of these antibodies suggests that effective T cell immunity is important to the immune defense against this pathogen.

An ideal vaccine is highly immunogenic, induces both T cell and B cell virus-specific immunity, and is free of irrelevant carrier proteins. While traditional approaches using whole virion or virion subunits can generally achieve this, practical considerations such as safety and availability of native antigen have led many to consider more highly engineered vaccine constructs for AIDS. Localization of immunodominant T cell and B cell recognition sites becomes critical if one wishes to design a vaccine based on recombinant proteins or synthetic peptides. A T cell response to the gp120 envelope protein has been demonstrated recently by Zarling et al. *Nature*, 323: 344-345 (1986) in macaques immunized with vaccinia constructs containing gp120 coding sequence. However, identification and characterization of immunodominant T cell sites within this 518 residue protein or other HIV proteins have not been reported.

Antibodies typically recognize the antigen in native conformation and can potentially recognize almost any site exposed on the antigen surface. In contrast, typical CD4+ helper T cells recognize antigen only in the context of the Class II Major Histocompatibility (MHC) molecule and only after appropriate antigen processing usually consisting of proteolysis or denaturation. Additionally, the polyclonal T cell response is focused only on relatively few discrete sites. This limited response is seen even for non-ukaryotic proteins

(e.g., influenza hemagglutinin and staphylococcal nuclease) for which tolerance to homologous host proteins does not limit the number of antigenic sites. Therefore, it is important to find sites which do elicit T-cell immunity to AIDS viral proteins. The elucidation of features determining immunodominance residing both intrinsic and extrinsic to antigen is the focus of much current basic and clinical interest. Detailed characterization of immunodominant T cell sites has allowed exploration for general features. Such analysis led to the observation that immunodominant T cell sites tend to have an amino acid sequence consistent with formation of an amphipathic helix with hydrophilic residues on one face and hydrophobic residues on the opposite face. In an amphipathic alpha helix, the hydrophobicity varies sinusoidally with a period of 3.6 residues per turn of the helix or a frequency of 100° per residue. An amphipathic  $\alpha_{10}$  helix has a period of 3 and a frequency of 120°. Based on this model, an algorithm entitled AMPHI has been developed for identification of such sequences in proteins given only primary sequence data.

Although Zarling et al., *Nature* 323: 344 (1986), showed that T cell immunity to the AIDS virus envelope could be induced in monkeys using a recombinant vaccinia virus carrying the gene for the whole envelope protein, their study did not identify antigenic sites stimulating these T cells. Also, vaccinia immunization has been discontinued in the United States because of danger of disseminated vaccinia infection and other side effects. A synthetic peptide vaccine would not carry any of these risks. Since it would be synthetic, there would be no risk of live AIDS virus contamination as might occur with a killed virus vaccine. A synthetic peptide which does not contain sites responsible for syncytia formation might produce fewer side effects than a large recombinant envelope protein containing such sites.

20 Summary of the Invention

The present invention relates to a method of inducing cellular immunity to native proteins of the AIDS virus by immunization with short synthetic peptides. Five potential peptides are identified by searching for 25 regions which can fold as a maximally amphipathic helix. Two of these are recognized by T cells immune to the AIDS virus envelope protein. One of these was used to immunize mice and can successfully induce T cell immunity to the whole AIDS envelope protein (480 amino acid residues long) using this 16-residue peptide in 3 of 4 mouse strains tested. The invention includes but is not limited to these specific peptides and any synthetic peptides containing or overlapping these sequences or variations therein, including 30 peptides with amino acid substitutions that retain or enhance the activity documented. These can be used alone as a vaccine or in combination with other materials (e.g. primary immunization with peptide, boost with recombinant fragment). They can also be attached to sites binding neutralizing antibodies to induce a neutralizing antibody response.

Specifically according to the invention there is provided isolated peptides or portions thereof adapted to 35 serve as components of a vaccine for acquired immune deficiency syndrome (AIDS), characterised in that said peptides are capable of inducing T cell response specific to acquired immunodeficiency syndrome (AIDS) virus and in that said peptides are selected from amino acid sequences in single letter code:

40 F N M W K N D M V E Q M H E D I I S L W D Q S L K P C V K L T L C V ;  
 KTFNGTGPCTNVSTVQCTHG; IRIQRGPGRAFVTIGKIGNMRQAH; RAKWNNTLQKIDSKLREQFGNNK; TLPCRIKQIINMWQEVGKAMYAP;  
 N N L L R A I E A Q Q H L L Q L T V W G I K ;  
 SNKSLEQIWNNTWMEWDREINNYTSЛИHSLIESQNQ;  
 E L L E L D K W A S L W N W F N I T N W L W Y ;  
 45 I V T R I V E L L G R R G W E A L K Y W W N L L Q Y W S Q E L K ;  
 D R V I E V V Q G A Y R A I R H I P R R I R Q G L E R I L L ; A S V L S G G E L D R W E K I R L R ;  
 E T S E G C R Q I L G Q L Q P S L Q T ; E I K D T K E A L D K I E E E Q N K ;  
 S P R T L N A W V K V V E E K ; D I R Q G P K E P F R D Y V D R F Y K T L R A E Q A ;  
 50 A R V L A E A M S Q V T N T A T I ; H E D I I S L W D Q S L K ; and  
 K Q I I N M W Q E V G K A M Y A ; and

T-cell sites env T<sub>1</sub>, residues 428-443, and env T<sub>2</sub>, residues 112-124, or portions thereof.

The present invention is critical to the manufacture of peptide vaccines capable of eliciting T-cell 55 immunity. One aspect of the present invention is the discovery of certain traits which seem to be common to most T-cell stimulating protein segments. Such peptide vaccines should optimally be those protein segments which (a) have a propensity to form amphipathic alpha-helices; (b) do not have regions with a propensity to coil formations; and (c) have a lysine at their COOH-terminus. The last two observations are of

particular use in manufacturing peptides vaccines: they indicate where the synthetic peptides should be terminated.

#### Description of the Figures

5 Figure 1 shows the HTLV-III gp160 envelope protein. The gp120 and gp41 proteins are shown along with recombinant proteins and synthetic peptides referred to in this study. Selected restriction site locations are shown on the map at the top along with the shaded leader peptide (1-37) and transmembrane region (519-534). The precursor gp160 is cleaved to form the gp120 and gp41 proteins. The dimensions and 10 locations of the R10 and PB1 recombinant proteins and the env T1 and T2 synthetic peptides examined in this study are shown. The locations of known B cell epitopes (B1 and B2) in the gp41 protein are also shown.

15 Figure 2 shows the results of AMPHI analysis in the region of the env T1 and env T2 sites.

15 Figure 3 shows lymph node proliferation assays of HTLV-III envelope gp120 and related recombinant and synthetic peptide antigens. F1 hybrid mice were immunized with either 10 micrograms of the large recombinant protein R10 (panels A and B labeled NP) or 3 nanomoles of peptide env T1 (panels C and D labeled PN) in 50 microliters of complete Freund's adjuvant (DIFCO, Detroit, MI) at the base of the tail. Eight days later the draining inguinal and periaortic lymph nodes were removed and a single cell suspension prepared. Assays were set up in quadruplicate with appropriate antigen in 96-well plates with 3 20  $\times 10^5$  cells per well in complete medium consisting of RPMI 1640 with 44% Eagle's-Hanks' amino acid medium, 10% fetal bovine serum,  $5 \times 10^{-5}$  M 2-mercaptoethanol, 2mM fresh-frozen L-glutamine (Gibco, Grand Island, NY), 100 U/ml penicillin, and 100 micrograms/ml streptomycin (Gibco). Plates were incubated for 4 days at 37° in a 5% CO<sub>2</sub> incubator, pulsed with 1 microCi of [<sup>3</sup>H]-thymidine (New England Nuclear, Boston MA) and harvested 18 hours later onto glass fiber paper. Thymidine incorporation into DNA was 25 then quantitated by liquid scintillation counting.

30 The geometric mean and standard error of the mean for each group were determined and the no antigen background subtracted to obtain the delta cpm. The no antigen backgrounds were: A: 21,771; B: 17,844; C: 30,674; D: 29,298. The confidence intervals for the background values are shown at the zero position of each vertical axis (n=8). The panels are scaled according to the magnitude of the PPD positive control response.

35 Figure 4 shows the response of env T1 peptide immune lymph node cells to gp120 and related antigens in the independent parental mouse strains. C57BL/6, C3H/HeJ, A.SW, and BALB/c mice were immunized with the 16-residue env T1 peptide and lymph node proliferation assays were performed as described in the legend to Figure 3. SW102 is a peptide representing sperm whale myoglobin residues 102-118. The no antigen (0) and PPD negative and positive controls are shown in the first position of each panel. The panels are scaled according to the magnitude of the PPD response. The no antigen backgrounds were: B6: 16,334, C3H: 74,253; A.SW: 28,771; BALB/c: 34,600.

40 Figure 5 shows alpha helical net representation of the env T2 and env T1 sites. This display can be thought of as slicing the cylinder of the helix lengthwise down one face, opening and flattening it. There are 3.6 residues per turn of the helix. The hydrophobic residues are shaded. Residues common to both sides are boxed. Regions outside of the peptides are shaded according to hydrophobicities of residues in the gp120 sequence.

#### Detailed Description of Preferred Embodiments of the Invention

45 Prediction of T-cell antigenic peptides has important implications for the development of artificial vaccines. Such vaccines are particularly useful in diseases like leprosy, caused by organisms which are hard to culture and for which the cellular arm of the immune system is the principal defense. Even when antibody production is the primary goal of vaccination, a secondary or anamnestic response requires the induction of helper T-cell immunity. Prediction of peptides for use as vaccines requires discovery and confirmation of properties correlating with T-cell antigenicity. One of the purposes of this invention is to use such properties in a process capable of reliably predicting T-cell stimulation by a protein segment.

50 T-cell immunity is not only important in the defense against many viral infections; T-cell help is also necessary for a memory antibody response. However, only a limited number of segments of protein antigens elicit T-cell immunity. None have previously been found for any proteins of the AIDS virus. The T-cell antigenic sites from AIDS viral proteins covered by the present invention should be very useful in any vaccine developed for this virus. The present invention also shows that one of the peptides elicits T-cell immunity to the native AIDS gp120 envelope protein. Thus, these peptides may constitute all or part of a

synthetic vaccine. Also, a fragment vaccine made by recombinant DNA or other technology should be designed to include these sites.

The experimental peptides containing the immunodominant sites are defined herein as antigenic sites. "Antigenicity" in this invention always refers to T-cell antigenicity.

5 In vivo, an antigenic protein probably passes through three main steps before raising a helper T-cell response: (a) "processing": an antigen-presenting cell (APC), usually a macrophage, dendritic or B cell, ingests the protein and then digests it into smaller peptides; (b) "presentation": these peptides are then presented to T-cells, probably in conjunction with a Class II Major Histocompatibility Complex Protein on the APC surface; and (c) "recognition": a helper T-cell receptor then recognizes some combination of peptide and Class II Protein, and initiates a T-cell response.

10 Two antigenic properties are thought to contribute to this process, amphipathicity and Alpha-helicity, based on the findings in this invention.

15 A structure is amphipathic when it has both a hydrophobic portion and hydrophilic portion. A peptide is segmentally amphipathic when the peptide contains at least two disjoint subpeptides, one hydrophobic, the other hydrophilic. A peptide is alpha-amphipathic if, when the peptide is put into an alpha-helical conformation, one side of the alpha-helix is hydrophobic, the other side hydrophilic. A peptide is helically amphipathic if, when put into an alpha or 3<sub>10</sub> helix, or similar helical structure, one side of the helix is hydrophobic and the other side hydrophilic. Both segmental amphipathicity and helical-amphipathicity are believed to contribute to T-cell antigenicity, though opinions about their relative importance differ.

20 AMPHI was used to analyze the gp120 envelope protein of the HTLV-IIIb isolates of HIV for sequences consistent with formation of amphipathic helices as potential T cell sites. Sites were ranked according to the apparent strength of helical amphipathicity as reflected in the Amphipathic Score, and frequencies were examined for consistency. Sites were further selected for occurrence in constant regions of gp120 (based on a comparison of the sequence of six isolates) and for absence of N-linked glycosylation sites. AMPHI 25 parameters for the two most favorable sites are shown in Figure 2. Candidate T cell sites were selected by including appropriate flanking residues. Candidate T cell sites env T1 and env T2 were defined as residues 428 through 443 and 112 through 124, respectively. The standard epitope nomenclature employed consists of viral isolate, protein designation, site type, and assigned number or residue number (e.g. HTLV-III (bH10)-env T1).

30 Synthetic peptides corresponding to these sites were prepared by solid phase peptide synthesis. Peptides were synthesized using standard methods of solid phase peptide synthesis on a Vega 250 peptide synthesizer using double dicyclohexylcarbodiimide mediated couplings. HOBT preactivation couplings were performed when coupling Gln or Asn. The standard t-boc/benzyl amino acid protection strategy was employed with side chain protection of the following amino acids: Asp(O-benzyl), Glu(O-benzyl), His(tosyl), 35 Lys(2-chlorobenzylcarbonyl), Ser(benzyl), Trp(formyl), Tyr(2,6-dichlorobenzyl). The extent of coupling was monitored using the qualitative ninhydrin test and recoupling performed when less than 99.4% coupling was observed. Peptides were cleaved from the resin using the low/high hydrogen fluoride (HF) method (J.P. Tam, W.F. Heath, and R.B. Merrifield, J. Am. Chem. Soc. 105, 6442 (1983)). For peptide env T2 standard HF cleavage was employed as removal of the tryptophan formyl protecting group was found not to be required for antigenic activity. Peptides were purified to homogeneity by gel filtration on Biogel P4 in 9% formic acid followed by reverse phase HPLC as described previously. Composition was confirmed and concentration determined by amino acid analysis. Native gp120 was purified by selective detergent extraction and immunoaffinity chromatography followed by dialysis. The recombinant proteins R10 and PB1 were produced by cloning restriction fragments KpnI(5923) to Bgl II(7197) or Pvu II(6659) to Bgl II(7197) 40 from the BH10 clone of HTLV-IIIb into the Repligen Expression Vector (REV) followed by expression in E. coli and purification. Protein R10 contains residues 49 through 474 and PB1 residues 294 through 474 of the envelope protein.

45 As a genetically defined model of an outbred population, there was studied the immune response to these proteins in (C57BL/6 x C3H/HeJ)F<sub>1</sub> and (A.SW x BALB/c)F<sub>1</sub> mice (H-2<sup>b<sub>1</sub></sup> and H-2<sup>s<sub>1</sub></sup> respectively). This strategy provides for full H-2 expression and complementation in the context of four different strain backgrounds. T cells have been shown to be responsible for the proliferation observed in antigen specific lymph node proliferation assays and consequently such assays were employed as a measure of T cell immunity.

50 Quantities of purified gp120 available precluded use in immunization and thus the R10 protein containing the majority of the gp120 sequence in nonglycosylated form was the largest immunogen used. Figure 3, panels A and B, shows the lymph node proliferative response of R10 immune mice tested with native gp120, recombinant proteins, and synthetic peptide env T1. In both F<sub>1</sub> hybrids a strong response was observed not only to the immunogen R10, but also to gp120. Therefore, the response was largely

directed at envelop sequ nce and not at the irr l vant vector-deriv d flanking sequenc ncoded r sidu s in the recombinant protein. Thus the recombinant R10-fragment is an effective immunogen for priming for a response to the native gp120. The response to the synthetic peptide env T1 indicates that a significant component of the T cell response to the 425 residue R10 is in fact focused on the 16 residue env T1 site.  
 5 In other experiments with R10 immune lymph node cells a response to peptide env T2 similar to that to peptide env T1 was observed (Table I).

TABLE I  
 10 RESPONSE TO ENV T2 PEPTIDE IN  
 R10(49-474)-IMMUNE F<sub>1</sub> HYBRID MICE  
 RELATIVE TO NATIVE gp120 and env T1 PEPTIDE

Hybrid Mice		
<u>Antigen</u>	<u>(B6 x C3H)F<sub>1</sub></u>	<u>(A.SW x BALB/c)F<sub>1</sub></u>
gp120	69,738 (1.01)	65,949 (1.07)
env T1	17,686 (1.12)	25,140 (1.15)
env T2	20,703 (1.18)	23,332 (1.14)
medium	10,864 (1.09)	13,381 (1.07)

[<sup>3</sup>H]-thymidine incorporation is shown for each group expressed as the geometric mean counts per minute with the standard error term for quadruplicate samples shown in parentheses. N = 8 for the medium controls. Antigen concentrations were 0.075 micromolar for gp120 and 4.8 micromolar for the env T1 and T2 peptides.

Given that immunization with a large fragment spanning most of the gp120 sequence elicits a response partially focused on a small site defined by a synthetic peptide (a native immunogen/peptide test-antigen or NP experiment), we next asked whether immunization with the synthetic peptide would elicit immunity to the native protein (a peptide immunogen/native test-antigen or PN experiment). Immunogenicity in the PN direction would appear to be a prerequisite for efficiency as a vaccine site. The results of such an experiment in the F<sub>1</sub> mice is shown in Figure 3, panels C and D. Mice immunized with env T1 peptide showed substantial immunity not only to the env T1 immunogen but also to the native gp120 as well as to the recombinant proteins. Thus a 16-residue synthetic peptide selected on the basis of amphipathicity can elicit T cell immunity to the native AIDS virus protein.

To further characterize genetic restriction of the response to env T1 there was studied the independent H-2 disparate parental strains from which the F<sub>1</sub> hybrids have been derived: C57BL/6, C3H/HeJ, A.SW and BALB/c. Mice were immunized with env T1 peptide and studied with native and peptide antigens. As shown in figure 4, C57BL/6 (H-2<sup>b</sup> haplotype) was found be a low responder, whereas the other strains (H-2<sup>k</sup>, H-2<sup>s</sup>, and H-2<sup>d</sup> haplotypes) were intermediate or high responders to the env T1 peptide. The response to native gp120 paralleled that to the peptide. A corresponding pattern of responsiveness is also observed in experiments using H-2 congenic strains of mice (Table II). Thus peptide env T1 represents a 16 residue peptide that can prime T cells for a secondary response to the 518 residue glycosylated native gp120 in 50 multiple MHC haplotypes.

TABLE II  
RESPONSE TO gp120 IN ENV T1  
PEPTIDE-IMMUNE H-2 CONGENIC MICE

Congenic Strains				
Antigen	B10.A(5R)	B10.BR	B10.S(9R)	B10.D2
PPD	85,511 (1.06)	100,872 (1.07)	71,006 (1.05)	44,564 (1.17)
gp120	45,857 (1.02)	69,456 (1.05)	68,219 (1.06)	64,858 (1.10)
medium	29,715 (1.03)	40,639 (1.04)	22,863 (1.04)	19,665 (1.06)

[<sup>3</sup>H]-thymidine incorporation is shown for each group expressed as the geometric mean counts per minute with the standard error term for quadruplicate samples shown in parentheses. N = 8 for the medium controls.

Antigen concentrations were 0.075 micromolar for gp120 and 32 micrograms per milliliter for PPD.

An unexpected finding was the striking cross reaction between env T1 and env T2 peptides. The env T1 immune cells responded to env T2 as well as to the immunizing peptide. Cross reactivity of env T2 was most pronounced on the H-2<sup>k</sup> haplotype. Prompted by this finding, the two sequences were compared and there was a degree of homology which was even more evident when considered in the context of possible alpha helical structure as shown in Figure 5. Not only do env T1 and env T2 share the hydrophobic Ile-Ile-Xxx-Yyy-Trp cluster on the hydrophobic face and the Lys on the hydrophilic face of the helix, but also the spatial relationship between these is identical. Gln and acidic amino acids (Glu, Asp) neighboring the Lys are observed in both cases as well. The poor reactivity to peptide 102-118 of sperm whale myoglobin which is derived from an unrelated protein and shares minimal homology with env T1 indicates that the property of being an amphipathic alpha-helical peptide is not sufficient for cross-reactivity. As an additional specificity control, gp120, env T1 and env T2 were tested using lymph node cells immune to an unrelated antigen, sperm whale myoglobin, and were found to be non-stimulatory (data not shown).

Though species differences are certain to influence the T cell repertoire, the molecules and mechanisms leading to a T cell response are conserved across species and thus the factors determining immunodominance are similar as well. The one helper T cell site (from influenza virus) that has been characterized at the synthetic peptide level in man is in fact immunodominant in mice as well and has no amino acid sequence consistent with formation of a highly amphipathic alpha helix.

Analysis of the various viral proteins in the thirteen HIV isolate sequences published shows the envelope gene to be the most variable. Such analysis reveals discrete variable and conserved regions. A polyvalent vaccine might thus be appropriate. Both the env T1 and the env T2 sites are highly conserved in the HIV sequences reported to date. The env T2 site is the more highly conserved of the two sites especially in the LAV<sub>ELI</sub> isolate. The previously described B cell sites (B1 and B2 in Figure 1) fall within conserved regions as well.

45 Induction of T cell immunity may contribute in several ways to protection against HIV infection. Though AIDS progresses despite the presence of detectable antibody to viral proteins in most patients, low titer neutralizing antibody has been demonstrated in many such patients. Neutralizing titers are substantially higher in healthy AIDS related complex patients and in HIV antibody positive hemophiliacs. Whether this relationship is causal or simply correlative is as yet unknown. If these or any other antibodies are in fact protective, provision of optimum T cell help at the time of immunization as well as when faced with an infectious challenge would appear essential. Substantial T cell help should also be required for an effective cell mediated response to infected cells. NK cells have been shown to selectively kill HIV infected cells *in vitro*. Given that a major mode of viral transmission in the infected patient is thought to be cell to cell, a vaccine that primes helper T cells for augmentation of NK cell and possibly lymphokine activated killer cell activity is essential for an effective vaccine. Induction of virus-specific cytotoxic T lymphocyte (CTL) 50 immunity, which also requires helper T cells, is also desirable. While in some cases the  $\alpha$  terminants recognized by CTL can in fact be defined by small peptides, *in vivo* expression of antigens such as in a vaccinia or adenoviral vector may be required for efficient elicitation of a classical CTL response. The AMPHI algorithm was developed to identify  $\alpha$  T cell sites, and consequently its relevance to CTL 55

specificity is unknown. However, it does successfully identify the two characterized sites in influenza nucleoprotein recognized by human and murine CTL.

The fact that helper T cell immunity can be induced with short peptides as well or better than with native protein stands in sharp contrast to the situation with B cell immunity for which tertiary structure is frequently important, and indicates that peptide vaccines aimed at T cell immunity are more successful than those aimed at antibody production. In a synthetic peptide or recombinant fragment based construct, one could selectively include important helper T cell sites, in multiple copies if desired, and exclude suppressor T cell sites which can blunt the immune response. Sites associated with specific functions or possible undesirable side effects such as the CD4 binding site(s), the site(s) mediating syncytia formation, or the neureleukin homology site, can be systematically included or excluded. For vaccines designed to induce antibodies as well as T cell immunity, incorporation of pathogen-derived T cell sites along with important B cell sites obviates the need to chemically couple small peptides to irrelevant carriers and disposes of coupling and carrier-derived problems. Thus the T cell sites identified here are potentially important components of an effective AIDS vaccine.

The present invention includes a method of predicting which segments of a protein (along its entire sequence, if desired) are antigenic. In other words, the present invention is a method of determining which sites of an entire protein sequence are recognized by T-cells (activate or stimulate T-cells). Application of this method is limited only by knowledge of the amino acid sequences of a protein, i.e., can be applied to any protein in the protein data base of the National Biomedical Research Foundation or any protein whose sequence is subsequently published. Moreover, the analysis can be done using the amino acid sequence translated from a DNA gene sequence, without ever isolating the protein. The background experiments which made this process possible comprise, in their entirety, an examination of a number of properties to determine if a particular property or properties is implicated in T-cell stimulation.

The following properties were determined to be fundamentally important (with a high degree of significance) in determining the potential immunogenicity of certain protein sequences:

- a. The helical amphipathicity of segments along the entire sequence of a protein;
- b. the conformational propensity of segments along the entire sequence of the protein;
- c. the presence or absence of helix-breakers in segments along the entire sequence of the protein; and
- d. the presence and location in the protein sequence of amino acid residues which favor T-cell recognition.

These properties were used to develop an optimized algorithm for detecting T-cell antigenic sites (based on the amphipathic helix model) in a protein with known sequences. The optimum algorithm identifies 18 of 23 known sites (75% sensitivity), with a high degree of significance ( $p < 0.001$ ). The success of the algorithm also shows that stable amphipathic structures such as amphipathic helices are fundamentally important in determining immunodominance. The optimized algorithm enables the prediction of immunodominant T-cell sites on a protein. This prediction capability facilitates the rational design of synthetic vaccines, and facilitates other approaches to antigen specific T-cell recognition.

## EXAMPLES

40

### Example 1

The AMPHI algorithm was used to examine the HTLV-III envelope protein amino acid sequence for sites with periodic variation in the hydrophobicity consistent with formation of an amphipathic helix (alpha or  $\beta_{10}$ ). Overlapping blocks of 11 residues were examined and resultant parameters assigned to the middle residue. The results for the residue 100-200 and 400-500 regions encompassing the env T2 and T1 sites respectively appear on the left and right of Figure 2. The upper panels show the amphipathic index, a measure of intensity of amphipathicity, determined at a frequency of  $100^\circ$  or  $120^\circ$  per residue. The higher of the two is shown. The lower panels display the frequency where the maximum amphipathic signal is observed. The sites were selected based on their consistently high amphipathic indices with maxima in the helical frequency range. The amino acid sequence of the indicated sites are: env T2(112-124): His-Glu-Asp-Ile-Ile-Ser-Leu-Trp-Asp-Gln-Ser-Leu-Lys; env T1(428-443): Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln-Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala.

55

### Example 2

Applying the algorithm is a major step in predicting the most probable immunodominant sites that show amphipathic helical potency. The number and length of sites along a specific protein depend on the

hydrophobicity profile of that protein. There are proteins that show a high degree of amphipathic helical potency (and contain many predicted sites), while others are poor in amphipathic segments. After having predicted all the possible amphipathic helical segments, the segments must be graded. The present invention prefers the use of three factors for grading purposes: a) amphipathic score (particularly useful when comparing segments of the same length); b) the rarity of proline in helices in general (except near the NH<sub>2</sub>-terminus), and in most of the helical antigenic sites in particular; and c) the appearance of lysine at the carboxyl end in a large number of helical antigenic sites. It has been found that lysine as the ultimate or penultimate C-terminal residue occurs much more frequently in immunodominant sites. In short, a preferred sequence contains amphipathic segments with proline, if present, only near the N-terminus, the lysine near the C-terminus.

Another possible indicator is the presence of N-glycosylation sites--these sites are indicative of a less favorable candidate for an immunodominant site, because the T-cell epitope may be masked by the carbohydrate.

15 Example 3

Using the process of this invention, the following segments were predicted to be T-cell stimulation sites:

1) segment 93-127

20 PheAsnMetTrpLysAsnAspMetValGluGlnMetHisGluAspIleIleSerLeu-

TrpAspGlnSerLeuLysProCysValLysLeuThrProLeuCysVal

25

2) segment 415-437

30 ThrLeuProCysArgIleLysGlnIleIleAsnMetTrpGlnGluValGlyLysAla-

MetTyrAlaPro

35 The numbering sequence used in this invention corresponds to Ratner et al, Nature, 313:277-284 (1985).

The underlined portion of each segment has been shown by other methods to be a T-cell stimulation site.

40 Example 4

The following segments from the envelope region of the HIV genome have been predicted as candidates for T-cell stimulation sites:

45	segment 231-250	segment 615-652
	segment 307-331	segment 659-681
	segment 335-357	segment 777-808
	segment 553-574	segment 827-856

50

The following segments from the gag region of the HIV genome have been predicted as candidates for T-cell stimulation sites:

55	segment 5-22	segment 148-162
	segment 52-70	segment 284-309
	segment 93-110	segment 360-376

The numbering sequence used in this invention corresponds to Ratner et al, Nature, 313:277-284 (1985).

The amino acid sequences for these peptides are shown in Table 3.

5

TABLE 3

From the env protein:

Segment 93-127

10

PheAsnMetTrpLysAsnAspMetValGluGlnMetHisGluAspIleIleSerLeu-  
TrpAspGlnSerLeuLysProCysValLysLeuThrProLeuCysVal

15

Segment 231-250

15

LysThrPheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHis-  
Gly

15

Segment 307-331

IleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGlyAsn-  
MetArgGlnAlaHisCys

20

Segment 335-357

ArgAlaLysTrpAsnAsnThrLeuLysGlnIleAspSerLysLeuArgGluGlnPhe-  
GlyAsnAsnLys

25

Segment 415-437

ThrLeuProCysArgIleLysGlnIleIleAsnMetTrpGlnGluValGlyLysAla-  
MetTyrAlaPro

Segment 553-574

30

AsnAsnLeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrp-  
GlyIleLys

Segment 615-652

35

SerAsnLysSerLeuGluGlnIleTrpAsnAsnMetThrTrpMetGluTrpAspArg-  
GluIleAsnAsnTyrThrSerLeuIleHisSerLeuIleGluGluSerGlnAsnGln

Segment 659-681

40

GluLeuLeuGluLeuAspLysTrpAlaSerLeuTrpAsnTrpPheAsnIleThrAsn-  
TrpLeuTrpTyr

40

Segment 777-808

IleValThrArgIleValGluLeuLeuGlyArgArgGlyTrpGluAlaLeuLysTyr-  
TrpTrpAsnLeuGlnTyrTrpSerGlnGluLeuLys

45

Segment 827-856

AspArgValIleGluValValGlnGlyAlaTyrArgAlaIleArgHisIleProArg-  
ArgIleArgGlnGlyLeuGluArgIleLeuLeu

From the gag protein:

50

Segment 5-22

AlaSerValLeuSerGlyGlyGluLeuAspArgTrpGluLysIleArgLeuArg

55

Segment 52-70

GluThrSerGluGlyCysArgGlnIleLeuGlyGlnLeuGlnProSerLeuGlnThr

Segment 93-110

GlulleLysAspThrLysGluAlaLeuAspLysIleGluGluGlnAsnLys

5 Segment 148-162

SerProArgThrLeuAsnAlaTrpValLysValValGluGluLys

Segment 284-30910 AspIleArgGlnGlyProLysGluProPheArgAspTyrValAspArgPheTyrLys-  
ThrLeuArgAlaGluGlnAlaSegment 360-376

15 AlaArgValLeuAlaGluAlaMetSerGlnValThrAsnThrAlaThrIle

---

Ala	A	Alanine	Leu	L	Leucine
Arg	R	Arginine	Lys	K	Lysine
Asn	N	Asparagine	Met	M	Methionine
Asp	D	Aspartic acid	Phe	F	Phenylalanine
Cys	C	Cysteine	Pro	P	Proline
Gln	Q	Glutamine	Ser	S	Serine
Glu	E	Glutamic acid	Thr	T	Threonine
Gly	G	Glycine	Trp	W	Tryptophan
25 His	H	Histidine	Tyr	Y	Tyrosine
Ile	I	Isoleucine	Val	V	Valine

30 **Claims**

1. Isolated peptides or portions thereof adapted to serve as components of a vaccine for acquired immune deficiency syndrome (AIDS), characterized in that said peptides are capable of inducing T cell response specific to acquired immunodeficiency syndrome (AIDS) virus and in that said peptides are selected from amino acid sequences in single letter code:

40 F N M W K N D M V E Q M H E D I I S L W D Q S L K P C V K L T L C V ;  
 KTFNGTGPCTNVSTVQCTHG; IRIQRGPGRAFVTIGKIGNMRQAH; RAKWNNTLKQIDSKLREQFGNNK; TLPCKRIKQIINMWQEVGKAMYAP;  
 N N L L R A I E A Q Q H L L Q L T V W G I K ; SNKSLEQIWNNTWMEWDREINNYTSLSIHSLIEESQNZ;  
 E L L E L D K W A S L W N W F N I T N W L W Y ; IVTRIVELLGRRGWEALKYWWNLLQYWSQELK;  
 45 DRVIEVVQGAYRAIRHIPRRIQGLERILL; ASVLSGGELDRWEKIRLR; ETSEGCRQILGQLQPSLQT; EIKDTKEALDKIEEEQNK; SPRTLNAWVKVVEEK; DIRQGPKEPFRDYVDRFYKTLRAEQA;  
 ARVLAEAMSQVTNTATI; HEDIISLWDQSLK; and KQIINMWQEVGKAMYA; and

50

T-cell sites HTLV-IIIb env T<sub>1</sub>, residues 428-443, and env T<sub>2</sub>, residues 112-124, or portions thereof.

55

2. Synthetic peptides comprising T cell sites HTLV-IIIb env T<sub>1</sub> and env T<sub>2</sub> which are residues 428-443 and 112-124, respectively, utilizing standard epitope nomenclatur .
3. Synthetic peptides corresponding to the sites of Claim 2.

4. Synthetic peptides substantially corresponding to the sites of Claim 2, or portions thereof.
5. Peptides according to any preceding claim wherein said peptides correspond to sequences from HIV viral proteins and when included in a vaccine, are capable of inducing T-cell immunity to acquired immune deficiency syndrome.  
5
6. The peptides of Claim 5, wherein said T-cell response is the induction of T-cell immunity.
7. The peptides of Claim 5, wherein said T-cell response is the induction of T-cell help for an antibody response.  
10
8. A synthetic peptide capable of eliciting a T-cell response, said peptide substantially corresponding to amino acid sequences 428-443 of the HIV envelope protein.
- 15 9. A synthetic peptide capable of eliciting a T-cell response, said peptide substantially corresponding to amino acid sequences 112-124 of the HIV envelope protein.
10. The preparation of synthetic peptides according to the sites of Claim 2, which includes the steps of defining peptides by searching for segments which have periodicity of hydrophobicity properties wherein said segments exhibit the capability to form amphipathic helices which are recognized by T cell antigenic sites, and synthesizing said peptides.  
20
11. Use of the peptides of Claim 1 in the preparation of a medicament for the treatment of AIDS.
- 25 12. Use of Claim 11, wherein said medicament is a vaccine.

**Patentansprüche**

1. Isolierte Peptide oder Teile hiervon, die dafür ausgebildet sind, als Komponenten eines Impfstoffs für das erworbene Immundefektsyndrom (AIDS) zu dienen, dadurch gekennzeichnet, daß die Peptide in der Lage sind, eine spezifische T-Zellen-Immunantwort auf den Virus des erworbenen Immundefektsyndroms (AIDS) zu induzieren, und daß die genannten Peptide aus Aminosäuresequenzen ausgewählt sind, die im Einbuchstabencode lauten:  
30

35

F N M W K N D M V E Q M H E D I I S L W D Q S L K P C V K L T L C V ;  
KTFNGTGPCTNVSTVQCTHG; IRIQRGPGRAFVTIGKIGNMRQAH;  
RAKWNNTLKQIDSKLREQFGNNK; TLPCKRIKQIINMWQEVGKAMYAP;  
N N L L R A I E A Q Q H L L Q L T V W G I K ;  
SNKSLEQIWNNTWMEWDREINNYTSLIHSLIEESQNZ;  
E L L E L D K W A S L W N W F N I T N N W L W Y ;  
I V T R I V E L L G R R G W E A L K Y W W N L L Q Y W S Q E L K ;  
DRVIEVVQGAYRAIRHIPRIRQGLERILL; ASVLSGGELDRWEKIRLR;  
40 ETSEGCRQILGQLQPSLQT; EIKDTKEALDKIEEEQNK;  
SPRTLNAWVKVVEEK; DIRQGPKEPFRDYVDRFYKTLRAEQA;  
45 ARVLAEEAMSQVTNTATI; HEDIISLWDQSLK; und  
KQIINMWQEVGKAMYA; und

50

T-Zellen-Mutationsbereiche HTLV-IIIb env T1, Reste 428-443, und env T2, Reste 112-124 oder Teile hiervon.

2. Synthetische Peptide mit T-Zellen-Mutationsbereichen HTLV-IIIb env T1 und env T2, wobei es sich um Reste 428-443 bzw. 112-124 handelt, unter Anwendung der Standard-Epitop nomenklatur.  
55
3. Synthetische Peptide entsprechend den Mutationsbereichen nach Anspruch 2.

4. Synthetische Peptide im wesentlichen entsprechend den Mutationsbereichen nach Anspruch 2 oder Teilen hiervon.

5. Peptide nach einem der vorhergehenden Ansprüche, wobei die genannten Peptide Sequenzen von HIV-Virusproteinen entsprechen und, wenn sie in einen Impfstoff eingebracht sind, in der Lage sind, eine T-Zellennimmunität gegen das erworbene Immundefektsyndrom zu induzieren.

10. Peptide nach Anspruch 5, wobei die T-Zellen-Immunantwort die Induktion von T-Zellen-Immunität ist.

15. Peptide nach Anspruch 5, wobei die T-Zellen-Immunantwort die Induktion von T-Zellen-Hilfe für eine Antikörper-Immunantwort ist.

20. Synthetisches Peptid, das in der Lage ist, eine T-Zellen-Immunantwort herbeizuführen, wobei das genannte Peptid im Wesentlichen den Aminosäuresequenzen 428-443 des HIV-Hüllproteins entspricht.

25. Synthetisches Peptid, das in der Lage ist, eine T-Zellen-Immunantwort beizuführen, wobei das genannte Peptid im wesentlichen den Aminosäuresequenzen 112 bis 124 des HIV-Hüllproteins entspricht.

30. Herstellung Synthetischer Peptide entsprechend den Mutationsbereichen nach Anspruch 2, welches die Schritte des Definierens von Peptiden durch Suchen nach Segmenten, die Periodizität von Hydrophobie-Eigenschaften haben, wobei die genannten Segmente die Fähigkeit zeigen, amphipatische Spiralen zu bilden, die von antigenen T-Zellenbereichen erkannt werden, und des synthetischen Herstellens der genannten Peptide umfaßt.

35. Verwendung der Peptide nach Anspruch 1 bei der Zubereitung eines Medikaments zur AIDS-Behandlung.

40. Verwendung nach Anspruch 11, wobei das Medikament ein Impfstoff ist.

### 30 Revendications

1. Peptides ou parties de peptides, à l'état isolé, adaptés pour être utilisés comme constituants d'un vaccin contre le syndrome d'immunodéficience acquise (SIDA), caractérisé en ce que lesdits peptides sont susceptibles d'induire une réponse des lymphocytes T, spécifique au virus du syndrome d'immunodéficience acquise, et en ce que lesdits peptides sont choisis parmi les séquences suivantes d'amino-acides identifiés selon le code à une lettre :

40 F N M W K N D M V E Q M H E D I I S L W D Q S I K P C V K L T L C V ;  
 KTFNGTGPCTNVSTVQCTHG; IRIQRGPGRAFVTIGKIGNMRQAH; RAKWNNTLQKIDSKLREQFGNNK; TLPCRIKQIINMWQEVGKAMYAP; N N L L R A I E A Q Q H L L Q L T V W G I K ; SNKSLEQIWNNTWMEWDREINNYTSLLIHSLLIEESQNQ; E L L E L D K W A S L W N W F N I T N W L W Y ; IVTRIVELLGRRGWEALKYWWNLLQYWSQELK; DRVIEVVQGAYRAIRHIPRRIRQGLERILL; ASVLSGGELDRWEKIRLR; ETSEGCRQILGQLQPSLQT; EIKDTKEALDKIEEEQNK; SPRTLNAWVKVVEK; DIRQGPKEPFRDYVDRFYKTLRAEQA; ARVLAEAMSQVTNTATI; HEDIISLWDQSLK; et KQIINMWQEVGKAMYA;

45 50

et parmi les fragments de HTLV-IIIb, 428-443, dits env T<sub>1</sub>, et 112-124, dits env T<sub>2</sub>, constituant des sites de combinaison avec des lymphocytes T, ou des parties desdits fragments.

55 2. Peptides de synthèse comprenant les segments de HTLV-IIIb, constituant des sites de combinaison avec des lymphocytes T, dits env T<sub>1</sub> et env T<sub>2</sub>, qui sont les fragments 428-443 et 112-124 respectivement, selon la nomenclature standard des épitopes.

3. Peptides de synthèse correspondant aux sites de combinaison selon la revendication 2, ou parties desdits sites.
4. Peptides de synthèse correspondant substantiellement aux sites de combinaison selon la revendication 5, ou parties desdits sites.
5. Peptides selon l'une quelconque des revendications précédentes, selon lesquels lesdits peptides correspondent à des séquences appartenant à des protéines du virus HIV, et susceptibles, lorsqu'incluses dans un vaccin, d'induire une immunité des lymphocytes T vis-à-vis du syndrome de l'immuno-déficience acquise.
6. Peptides selon la revendication 5, selon lesquels ladite réponse des lymphocytes T est l'induction d'une immunité des lymphocytes T.
7. Peptides selon la revendication 5, selon lesquels ladite réponse des lymphocytes T est l'induction des lymphocytes T auxiliaires en vue d'une réponse avec un anticorps.
8. Peptide de synthèse susceptible d'induire une réponse des lymphocytes T, ledit peptide correspondant substantiellement aux séquences 428-443 d'aminoacides de la protéine d'enveloppe de HIV.
9. Peptide de synthèse susceptible d'induire une réponse des lymphocytes T, ledit peptide correspondant substantiellement aux séquences 112-124 d'aminoacides de la protéine d'enveloppe de HIV.
10. Préparation de peptides de synthèse correspondant aux sites de combinaison selon la revendication 2, comprenant les étapes suivantes :
  - détermination des peptides en recherchant les segments présentant périodiquement un caractère hydrophobe, et manifestant la possibilité de se conformer en hélices amphiphiles, reconnues par des sites de combinaison antigénique des lymphocytes T
  - et synthèse desdits peptides.
11. Utilisation des peptides selon la revendication 1, pour préparer un médicament pour le traitement du SIDA.
12. Utilisation selon la revendication 1, selon laquelle ledit médicament est un vaccin.

35

40

45

50

55




Fig. 1




Fig. 2

RESIDUE NUMBER




Fig. 3

PROLIFERATIVE RESPONSE  
OF PEPTIDE 428-443-IMMUNE LYMPH NODE CELLS




Fig. 4




Fig. 5